Velavigo
Latest round
- Angel
Last raised
- Nov 2021
Total raised
- $50M
Investors
- 5
About Velavigo
Founded in 2021 and based in Shanghai, China by Dr. Jing Li, who previously held senior R&D roles at Pfizer and Novartis. Velavigo specializes in the development of multispecific antibodies and antibody-drug conjugates (ADC) for oncology and autoimmune diseases, leveraging proprietary platforms to advance differentiated biologics with first-in-class (FIC) and best-in-class (BIC) potential. The company develops multispecific antibodies and ADC therapies aimed at treating cancer and immune-related diseases. The company generates revenue through research and development partnerships, technology licensing and milestone-based collaboration deals involving its pipeline of antibody-based therapies.
Who invested in Velavigo
5 investors across 1 round
See all investors in Velavigo
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Nov 15, 2021
Amount
$50M
Investors
Questions about Velavigo
Who invested in Velavigo?
Velavigo has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Velavigo raised?
Velavigo has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Velavigo last raise money?
Velavigo's most recent round on record is a Angel, in Nov 2021.
What does Velavigo do?
Founded in 2021 and based in Shanghai, China by Dr.
Where is Velavigo headquartered?
Velavigo is headquartered in Shanghai, China.
Which VCs invest in companies like Velavigo?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at Velavigo's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like Velavigo? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.